Orforglipron for Type 2 Diabetes Mellitus: Current Evidence, Clinical Benefits, and Future Prospects

Sagar*1, Mr.Hans Raj 2, Dr. Jyoti Gupta 3

1.Research Scholar, IEC School of Pharmacy, IEC University, Baddi, Solan, H.P, 174103

2.Associate Professor, IEC School of Pharmacy, IEC University, Baddi, Solan, H.P, 174103

3.Head of Department, IEC School of Pharmacy, IEC University, Baddi, Solan, H.P, 174103

Correspondance Author

Sagar

1.Affiliation:- Research Scholar, IEC School of Pharmacy, IEC University, Baddi, Solan, H.P, 174103

2.E-mail:- sagarlubana06142@gmail.com

Abstract

Persistent hyperglycemia brought on by decreased insulin secretion, action, or both is a hallmark of diabetes mellitus, a chronic metabolic disease. Obesity, insulin resistance, β-cell dysfunction, and a higher risk of cardiovascular and renal problems are all directly linked to Type 2 diabetes mellitus (T2D), one of its major types. By enhancing glucose-dependent insulin secretion, inhibiting glucagon release, postponing stomach emptying, encouraging satiety, and aiding in weight loss, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of type 2 diabetes. However, the requirement for injections and gastrointestinal side effects prevent injectable GLP-1RAs from being widely used. To get around these restrictions while preserving the therapeutic advantages of GLP-1 receptor activation, a novel oral non-peptide small-molecule GLP-1 receptor agonist called Orforglipron was created. The pharmacological mechanism, clinical efficacy, safety, and prospective therapeutic use of orforglipron in the treatment of obesity and type 2 diabetes are all summarized in this review. Clinical data shows favorable effects on cardiovascular risk biomarkers, such as improvements in high-density lipoprotein cholesterol and decreases in blood pressure, triglycerides, and low-density lipoprotein cholesterol, as well as notable decreases in glycated hemoglobin (HbA1c), fasting plasma glucose, and body weight. Dose-dependent gastrointestinal side effects, such as nausea, vomiting, and diarrhea, which are typically mild to moderate and temporary, are the main characteristics of the safety profile. In contrast to many peptide GLP-1 receptor agonists, orforglipron has not yet shown any signs of pancreatitis or ocular problems; nonetheless, ongoing post-marketing surveillance is still crucial. The lack of long-term real-world effectiveness data, underrepresentation of high-risk patient populations, and very short study durations limit the available evidence, notwithstanding these positive results. All things considered, orforglipron is a promising oral GLP-1 receptor agonist that may enhance treatment compliance and increase therapeutic alternatives for individuals with obesity and type 2 diabetes. To determine its cardiovascular results, long-term safety, and efficacy in a variety of patient populations, further extensive research is needed.

Keywords: Orforglipron; Type 2 Diabetes Mellitus; GLP-1 Receptor Agonist; Oral Antidiabetic Therapy; Glycemic Control; Obesity; Weight Loss; Cardiovascular Risk.